Database
User
| Compound | Dose | Time | Species | Model | Method | Result | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| Nimesulide | 1 mM | rat; Sprague-Dawley Crl:CD (SD) BR | lung microsomes | adrenochrome assay (Misra and Fridovich, 1972) | Positive | p < 0.05 | 11 | |
| Nimesulide | 0.5 mM | 20 minutes | rat; Sprague-Dawley Crl:CD (SD) BR | lung microsomes | horseadish preoxidase method (Green and Hill, 1984) | Positive | p < 0.05 | 11 |
| Zidovudine | Positive | 307 | ||||||
| Acyclovir | Positive | 307 | ||||||
| Ganciclovir | Positive | 307 | ||||||
| Zalcitabine | Positive | 307 | ||||||
| Sulindac | Positive | 45 | ||||||
| Ciprofloxacin | Positive | 307 | ||||||
| Cisplatin | Positive | 307 | ||||||
| Cyclophosphamide | Positive | 307 | ||||||
| Paraquat | 10 mM | yeast; EG103 (Wild-type) | mitochondria | Measurement of superoxide anion | Negative | 14 | ||
| Paraquat | 10 mM | yeast; EG103 (Wild-type) | mitochondria | Measurement of superoxide anion; Used ethanol (5 mM) as substrate | Negative | 14 | ||
| Paraquat | 10 mM | yeast; EG110 (MnSOD knock-out) | mitochondria | Measurement of superoxide anion; Used ethanol (5 mM) as substrate | Positive | 14 | ||
| Paraquat | 10 mM | yeast; EG103 (Wild-type) | mitochondria | Measurement of superoxide anion; Used ethanol (5 mM) as substrate | Positive | 14 | ||
| Paraquat | 10 mM | yeast; EG103 (Wild-type) | mitochondria | Measurement of superoxide anion; Used ethanol (5 mM) as substrate; Used FCCP (1μm) as uncoupler | Negative | 14 | ||
| Paraquat | 1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of superoxide anion; Used glutamate/malate (5 mM) as substrate | Positive | 14 | |
| Paraquat | 1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of superoxide anion; Used glutamate/malate (5 mM) as substrate; Used FCCP (1μm) as uncoupler | Negative | 14 | |
| Paraquat | 0.1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of superoxide anion; Used succinate (5 mM) as substrate | Positive | 14 | |
| Paraquat | 1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of superoxide anion; Used succinate (5 mM) as substrate; Used FCCP (1μm) as uncoupler | Negative | 14 | |
| Paraquat | 0.1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of superoxide anion; Used succinate (5 mM) as substrate; Used rotenone (4μm) as inhibiter | Negative | 14 | |
| Paraquat | 1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of hydrogen peroxide; Used glutamate/malate (5 mM) as substrate | Positive | 14 | |
| Paraquat | 1 mM | 10 minutes | rat | isolated heart mitochondria | Measurement of hydrogen peroxide; Used succinate (5 mM) as substrate | Positive | 14 | |
| Caffeine | > 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Negative | MEC | 306 |
| citrate | > 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Negative | MEC | 306 |
| Etoposide | > 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Negative | MEC | 306 |
| Metformin | 500 μM | 24 hours | human | hepatocytes | ROS measurement | Negative | 15 | |
| Metformin | 1 mM | 24 hours | human | hepatocytes | ROS measurement | Positive | 15 | |
| Metformin | 2 mM | 24 hours | human | hepatocytes | ROS measurement | Positive | 15 | |
| buformin | 75 μM | 24 hours | human | hepatocytes | ROS measurement | Positive | 15 | |
| Phenformin | 12.5 μM | 24 hours | human | hepatocytes | ROS measurement | Positive | 15 | |
| Rotenone | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Amiodarone | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Chlorpromazine | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Cyclosporin A | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| imipramine | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Maprotiline | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Tamoxifen | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Troglitazone | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| atorvastatin | 100 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Cerivastatin | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| fluvastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Acetylsalicylic acid | 5 μmol/ml | 24 hours | human | HepG2 | ROS measurement | Negative | p < 0.05 | 2 |
| Acetylsalicylic acid | 5 μmol/ml | 48 hours | human | HepG2 | ROS measurement | Negative | p < 0.05 | 2 |
| Acetylsalicylic acid | 10 μmol/ml | 24 hours | human | HepG2 | ROS measurement | Positive | p < 0.05 | 2 |
| Acetylsalicylic acid | 10 μmol/ml | 48 hours | human | HepG2 | ROS measurement | Positive | p < 0.05 | 2 |
| lovastatin | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| pravastatin | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |
| Simvastatin | 5 µM | 1 hour | Human | HepG2 | High-content screening assay | Positive | MEC | 306 |